Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome
Hua Medicine Ltd (2552 HK) which specialises in developing drugs to treat Type 2 diabetes, is the third pre-profit biotech firm to IPO in Hong Kong...
974 Views
ECM Weekly (1 September 2018) - Meituan, NIO, Aavas, Hua Medicine, Qutoutiao
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
682 Views
Hua Medicine (华领医药) IPO: Little Upside to Fair Value
Hua Medicine launched the institutional book building today and intends to raise USD 111 to USD 124 million, with an implied market capitalization...
605 Views
Hua Medicine (华领医药) IPO: Thoughts on Valuation
Hua Medicine recently received approval for its listing application to raise USD 200 million. In our previous insight (Hua Medicine (华领医药) IPO:...
655 Views
Hua Medicine (华领医药) IPO: Reviving Roche's Failed Attempt?
Hua Medicine, a China-based drug development with type 2 diabetes drug in its pipeline, plans to list on the Hong Kong Stock Exchange. The company...
1.3k Views